Merck forges data analytics partnership with Palantir

pharmafile | January 17, 2017 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Merck, Palantir 

Merck has teamed up with software and data-mining firm Palantir with the intention to utilise its data analytics services to bolster its own drug R&D capabilities.

The partnership will focus on cancer treatment and patient services initially and will work together to develop a data analytics platform to hone drug development and ensure patient gain access to key drugs as soon as possible. The two companies ultimately aim to launch three initiatives including medical research and drug development, global patient intimacy and global supply chain.

“As a science and technology company, we are tackling the greatest challenges in healthcare, life science and performance materials,” explained Merck executive board chairman and CEO Stefan Oschmann. “Now we are teaming up with Palantir since developing breakthrough technologies requires superior data analytics capabilities, and Palantir optimally complements our skills in that respect.”

Palantir founder and CEO Alexander Karp added: “At the heart of Palantir’s mission is the desire to bring new tools to solve the world’s most difficult problems. When something like cancer is killing 8.2 million people each year, we want to do everything we can to apply our technological expertise to the fight, alongside partners who have been there since the beginning. We are pleased to have found a partner that shares our values and vision.”

Matt Fellows

Related Content

Merck’s Keytruda approved by EC for gastric cancer

Merck (known as MSD outside of the US and Canada) has announced the approval of …

Lynparza granted approval to treat prostate cancer in Japan

AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from …

Merck announces phase 3 LITESPARK-005 trial met primary endpoint

Merck (known as MSD outside of the US and Canada) has shared topline results from …

Latest content